Calendar No. 607

105TH CONGRESS S. 2151

A BILL

To clarify Federal law to prohibit the dispensing or distribution of a controlled substance for the purpose of causing, or assisting in causing, the suicide, euthanasia, or mercy killing of any individual.

September 24, 1998

Reported with an amendment and an amendment to the title $% \left(\mathbf{r}\right) =\mathbf{r}^{\prime }$

Calendar No. 607

105TH CONGRESS 2D SESSION

S. 2151

To clarify Federal law to prohibit the dispensing or distribution of a controlled substance for the purpose of causing, or assisting in causing, the suicide, euthanasia, or mercy killing of any individual.

IN THE SENATE OF THE UNITED STATES

June 9, 1998

Mr. Nickles (for himself, Mr. Lott, Mr. Coats, Mr. Inhofe, Mr. Helms, Mr. Murkowski, Mr. Grams, Mr. Faircloth, Mr. Bond, Mr. Enzi, Mr. Sessions, Mr. Hagel, Mr. Coverdell, Mr. Smith of New Hampshire, Mr. Lieberman, Mr. Brownback, Mr. Craig, Mr. Abraham, Mr. Santorum, Mr. Allard, Mr. Grassley, Mr. Dewine, Mr. Kyl, and Mr. Hutchinson) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

SEPTEMBER 24, 1998

Reported by Mr. Hatch, with an amendment and an amendment to the title [Strike out all after the enacting clause and insert the part printed in italic]

A BILL

To clarify Federal law to prohibit the dispensing or distribution of a controlled substance for the purpose of causing, or assisting in causing, the suicide, euthanasia, or mercy killing of any individual.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,

SECTION 1 SHORT TITLE

1	SECTION 1. SHORT TITLE.
2	This Act may be cited as the "Lethal Drug Abuse
3	Prevention Act of 1998".
4	SEC. 2. FINDINGS; PURPOSES.
5	(a) FINDINGS.—Congress finds that—
6	(1) the use of certain narcotics and other dan-
7	gerous drugs is generally prohibited under the Con-
8	trolled Substances Act;
9	(2) under the Controlled Substances Act and
10	implementing regulations, an exception to this gen-
11	eral prohibition permits the dispensing and distribu-
12	tion of certain controlled substances by properly reg-
13	istered physicians for legitimate medical purposes;
14	(3) the dispensing or distribution of controlled
15	substances to assist suicide is not a legitimate medi-
16	eal purpose and should not be construed to be per-
17	missible under the Controlled Substances Act;
18	(4) the dispensing or distribution of certain
19	controlled substances for the purpose of relieving
20	pain and discomfort is a legitimate medical purpose
21	under the Controlled Substances Act and physicians
22	should not hesitate to dispense or distribute them
23	for that purpose when medically indicated; and
24	(5) for the reasons set forth in section 101 of
25	the Controlled Substances Act (21 U.S.C. 801), the

dispensing and distribution of controlled substances

- 1 for any purpose, including that of assisting suicide, 2 affects interstate commerce. 3 (b) Purposes.—The purposes of this Act are— 4 (1) to provide explicitly that Federal law is not 5 intended to license the dispensing or distribution of 6 a controlled substance with a purpose of causing, or 7 assisting in causing, the suicide, euthanasia, or 8 mercy killing of any individual; and 9 (2) to encourage physicians to prescribe con-10 trolled substances as medically appropriate in order 11 to relieve pain and discomfort, by reducing unwar-12 ranted concerns that their registration to prescribe 13 controlled substances will thereby be put at risk, if 14 there is no intent to cause a patient's death. 15 SEC. 3. LETHAL DRUG ABUSE PREVENTION. 16 (a) DENIAL OF REGISTRATION.—Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following: 18
- 19 "(i) DENIAL OF REGISTRATION.—The Attorney Gen20 eral shall determine that registration of an applicant
 21 under this section is inconsistent with the public interest
 22 if—
- 23 "(1) during the 5-year period immediately pre-24 ceding the date on which the application is submit-25 ted under this section, the registration of the appli-

1	eant under this section was revoked under section
2	304(a)(4); or
3	"(2) the Attorney General determines, based on
4	elear and convincing evidence, that the applicant is
5	applying for the registration with the intention of
6	using the registration to take any action that would
7	constitute a violation of section 304(a)(4).".
8	(b) Suspension or Revocation of Registra-
9	TION.
10	(1) In General.—Section 304(a) of the Con-
11	trolled Substances Act (21 U.S.C. 824(a)) is amend-
12	ed—
13	(A) by redesignating paragraphs (4) and
14	(5) as paragraphs (5) and (6), respectively; and
15	(B) by inserting after paragraph (3) the
16	following:
17	"(4) has intentionally dispensed or distributed a
18	controlled substance with a purpose of causing, or
19	assisting in causing, the suicide, cuthanasia, or
20	mercy killing of any individual, except that this
21	paragraph does not apply to the dispensing or dis-
22	tribution of a controlled substance for the purpose of
23	relieving pain or discomfort (even if the use of the
24	controlled substance may increase the risk of death),
25	so long as the controlled substance is not also dis-

1	pensed or distributed for the purpose of causing, or
2	assisting in causing, the death of an individual for
3	any reason;".
4	(2) Conforming Amendment.—Section
5	304(a)(5) of the Controlled Substances Act (21
6	U.S.C. 824(a)(5)) (as redesignated by paragraph (1)
7	of this subsection) is amended by inserting "other"
8	after "such".
9	(e) PAIN RELIEF.—Section 304(e) of the Controlled
10	Substances Act (21 U.S.C. 824(c)) is amended—
11	(1) by striking "(e) Before" and inserting the
12	following:
13	"(e) Procedures.—
14	"(1) Order to show cause.—After any hear-
15	ing under paragraph (2), and before"; and
16	(2) by adding at the end the following:
17	"(2) MEDICAL REVIEW BOARD ON PAIN RE-
18	LIEF.
19	"(A) IN GENERAL.—The Attorney General
20	shall by regulation establish a board to be
21	known as the Medical Review Board on Pain
22	Relief (referred to in this subsection as the
23	'Board').
24	"(B) MEMBERSHIP. The Attorney Gen-
25	eral shall appoint the members of the Board—

"(i) from among individuals who, by reason of specialized education or substantial relevant experience in pain management, are clinical experts with knowledge regarding standards, practices, and guidelines concerning pain relief; and

"(ii) after consultation with the American Medical Association, the American Academy of Hospice and Palliative Medicine, the National Hospice Organization, the American Geriatrics Society, and such other entities with relevant expertise concerning pain relief, as the Attorney General determines to be appropriate.

"(C) DUTIES OF BOARD.—

"(i) Hearing.—If an applicant or registrant claims that any action (or, in the case of a proposed denial under section 303(i)(2), any potential action) that is a basis of a proposed denial under section 303(i), or a proposed revocation or suspension under subsection (a)(4) of this section, is an appropriate means to relieve pain that does not constitute a violation of subsection (a)(4) of this section, the appli-

cant or registrant may seek a hearing before the Board on that issue.

"(ii) FINDINGS.—Based on a hearing under clause (i), the Board shall make findings regarding whether the action at issue is an appropriate means to relieve pain that does not constitute a violation of subsection (a)(4). The findings of the Board under this clause shall be admissible in any hearing pursuant to an order to show cause under paragraph (1).".

SEC. 4. CONSTRUCTION.

- 13 (a) In General.—Nothing in this Act or the amend14 ments made by this Act shall be construed to imply that
 15 the dispensing or distribution of a controlled substance be16 fore the date of enactment of this Act for the purpose of
 17 causing, or assisting in causing, the suicide, cuthanasia,
 18 or mercy killing of any individual is not a violation of the
 19 Controlled Substances Act (21 U.S.C. 801 et seq.).
- 20 (b) Incorporated Definitions.—In this section,
 21 the terms "controlled substance", "dispense", and "dis22 tribute" have the meanings given those terms in section
 23 102 of the Controlled Substances Act (21 U.S.C. 802).

1 SECTION 1. SHORT TITLE.

2	This Act may be cited as the "Lethal Drug Abuse Pre-
3	vention Act of 1998".
4	SEC. 2. FINDINGS; PURPOSES.
5	(a) Findings.—Congress finds that—
6	(1) the use of certain narcotics and other drugs
7	or substances with a potential for abuse is strictly
8	regulated under the Controlled Substances Act;
9	(2) the dispensing and distribution of certain
10	controlled substances only by properly registered prac-
11	titioners only for legitimate medical purposes are per-
12	mitted under the Controlled Substances Act and im-
13	plementing regulations;
14	(3) the dispensing or distribution of controlled
15	substances to assist suicide or euthanasia are not le-
16	gitimate medical purposes and are not permissible
17	under the Controlled Substances Act;
18	(4) the dispensing or distribution of certain con-
19	trolled substances for the purpose of relieving pain
20	and discomfort are legitimate medical purposes and
21	are permissible under the Controlled Substances Act;
22	(5) inadequate treatment of pain, especially for
23	chronic diseases, irreversible diseases such as cancer,
24	and end-of-life care, is a serious public health problem
25	affecting hundreds of thousands of patients every

year; physicians should not hesitate to dispense or

- distribute controlled substances when medically indi cated for those conditions; and
- 3 (6) for the reasons set forth in section 101 of the 4 Controlled Substances Act (21 U.S.C. 801), the dis-5 pensing and distribution of controlled substances for 6 any purpose, including that of assisting suicide or eu-7 thanasia, affect interstate commerce.

8 (b) Purposes.—The purposes of this Act are—

- (1) to provide explicitly that Federal law is not intended to allow the dispensing or distribution of any controlled substance with the purpose of causing, or assisting in causing, the suicide or euthanasia, of any individual; and
- 14 (2) to encourage practitioners to prescribe, dis-15 pense, distribute, and administer controlled sub-16 stances as medically appropriate in order to relieve 17 pain and discomfort, by reducing unwarranted con-18 cerns that their registration to prescribe controlled 19 substances will thereby be put at risk, if there is no 20 intent to assist in causing a patient's death.

21 SEC. 3. LETHAL DRUG ABUSE PREVENTION.

(a) ADDITIONAL GROUND FOR DENIAL OF REGISTRATION.—Section 303 of the Controlled Substances Act (21
U.S.C. 823) is amended by adding at the end the following:

9

10

11

12

1	"(i) The Attorney General shall determine that reg-
2	istration of an applicant under this section is inconsistent
3	with the public interest if—
4	"(1) during the 5-year period immediately pre-
5	ceding the date on which the application is submitted
6	under this section, the registration of the applicant
7	under this section was suspended or revoked under
8	section $304(a)(4)$; or
9	"(2) the Attorney General determines, based on
10	clear and convincing evidence, that the applicant is
11	applying for the registration with the intention of
12	using the registration to take any action that would
13	constitute a violation of section $304(a)(4)$.".
14	(b) Suspension or Revocation of Registra-
15	TION.—
16	(1) In general.—Section 304(a) of the Con-
17	trolled Substances Act (21 U.S.C. 824(a)) is amend-
18	ed—
19	(A) by redesignating paragraphs (4) and
20	(5) as paragraphs (5) and (6), respectively; and
21	(B) by inserting after paragraph (3) the fol-
22	lowing:
23	"(4) has intentionally dispensed or distributed a
24	controlled substance with the purpose of causing, or
25	assisting in causing, the suicide or euthanasia of any

1	individual, except that this paragraph does not apply
2	to the dispensing or distribution of a controlled sub-
3	stance—
4	"(A) for the purpose of alleviating pain or
5	discomfort (even if the use of the controlled sub-
6	stance may increase the risk of death), so long
7	as the controlled substance is not also dispensed
8	or distributed for the purpose of causing, or as-
9	sisting in causing, the death of an individual for
10	any reason; or
11	"(B) for the purpose of carrying out a sen-
12	tence of death under Federal or State law;".
13	(2) Conforming amendment.—Section
14	304(a)(5) of the Controlled Substances Act (21 U.S.C.
15	824(a)(5)) (as redesignated by paragraph (1) of this
16	subsection) is amended by inserting "other" after
17	"such" the first place the term appears.
18	(c) Pain Relief.—Section 304(c) of the Controlled
19	Substances Act (21 U.S.C. 824(c)) is amended—
20	(1) by striking "(c) Before" and inserting the fol-
21	lowing:
22	"(c) Procedures.—
23	"(1) Order to show cause.—Before"; and
24	(2) by adding at the end the following:
25	"(2) Assisted suicide.—

1	"(A) FINDINGS.—
2	"(i) In general.—Prior to any pro-
3	ceeding under paragraph (1), where an
4	order to show cause may be based on sub-
5	section (a)(4) for denial, revocation, or sus-
6	pension of registration, the Attorney Gen-
7	eral shall make a finding that the applicant
8	or registrant—
9	"(I) has dispensed or distributed
10	a specific controlled substance that was
11	directly responsible for the death of an
12	individual; and
13	"(II) did not dispense or distrib-
14	ute the specific controlled substance as
15	$medically\ indicated.$
16	"(ii) Consultation.—In making any
17	finding under clause (i)(II), the Attorney
18	General may consult with the Secretary of
19	Health and Human Services, as the Attor-
20	ney General, in consultation with the Sec-
21	retary, determines to be appropriate.
22	"(B) Burden of proof.—At any proceed-
23	ing under paragraph (1), where the order to
24	show cause is based on subsection (a)(4) for de-
25	nial, revocation, or suspension of registration,

the Attorney General shall have the burden of proving, by clear and convincing evidence, that the practitioner's intent was to dispense or distribute a controlled substance with a purpose of causing, or assisting in causing, the suicide or euthanasia of any individual. In meeting such burden, it shall not be sufficient to prove that the registrant knew that the use of controlled substance may increase the risk of death.

- "(C) REQUEST FOR REVIEW BY MEDICAL ADVISORY BOARD ON PAIN RELIEF.—At any proceeding under paragraph (1), where the order to show cause is based on subsection (a)(4) for denial, revocation, or suspension of registration, the practitioner may request, within 30 days after the receipt of the order to show cause, that the Medical Advisory Board on Pain Relief review, in accordance with paragraph (3), the administrative record of such proceeding as it relates to subsection (a)(4).
- "(3) Medical advisory board on pain relief.—
- 23 "(A) IN GENERAL.—The Secretary of 24 Health and Human Services, in consultation 25 with the Attorney General, shall by regulation

1	establish a board to be known as the Medical Ad-
2	visory Board on Pain Relief (referred to in this
3	subsection as the 'Board').
4	"(B) Membership.—
5	"(i) In general.—Subject to clause
6	(ii), the Secretary of Health and Human
7	Services, in consultation with the Attorney
8	General, shall appoint the members of the
9	Board—
10	"(I) from among individuals who
11	by reason of specialized education or
12	substantial relevant experience in pain
13	management, are clinical experts with
14	knowledge regarding standards, prac-
15	tices, and guidelines concerning pain
16	relief; and
17	"(II) after consultation with the
18	American Medical Association, the
19	American Academy of Pain Medicine,
20	the American Pain Society, the Amer-
21	ican Academy of Hospice and Pallia-
22	tive Medicine, the National Hospice
23	Organization, the American Geriatrics
24	Society, and such other entities with
25	relevant expertise concerning pain re-

1	lief, as the Attorney General deter-
2	mines to be appropriate.
3	"(ii) Prohibition.—No member of the
4	Board may be an officer or employee of the
5	Federal Government.
6	"(C) Duties of Board.—If, in accordance
7	with paragraph (2)(B), an applicant or reg-
8	istrant requests a review by the Board of the
9	record of a proceeding under paragraph (1), the
10	Board shall review the administrative record of
11	such proceeding as it relates to subsection (a)(4)
12	and issue to the Secretary of Health and Human
13	Services and the Attorney General an advisory
14	opinion as to whether the dispensing or distribu-
15	tion of the controlled substance at issue in the
16	proceeding was for the purpose of alleviating
17	pain or discomfort in a manner that does not
18	constitute a violation of subsection (a)(4). The
19	opinion of the Board under this subparagraph
20	shall be part of the administrative record and
21	shall be considered by the Attorney General in
22	determining whether to deny, revoke, or suspend
23	the registration involved.
24	"(D) Compsensation of members.—Each
25	member of the Board shall be compensated at a

rate equal to the daily equivalent of the annual rate of basic pay prescribed for level IV of the Executive Schedule under section 5315 of title 5, United States Code, for each day (including

5 travel time) during which such member is en-

6 gaged in the performance of the duties of the

 $7 ext{ } Board.$

- "(4) NO ADDITIONAL INVESTIGATIVE AUTHORITY.—Nothing in section 303(i), subsection (a)(4) of
 this section, or this subsection may be construed to
 provide the Attorney General with any additional investigative authority in any State, to the extent that
 the law of the State prohibits assisted suicide or euthanasia."
- 15 SEC. 4. DESIGNATION OF LIAISON.
- Not later than 30 days after the date of enactment of
- 17 this Act, the Secretary of Health and Human Services shall
- 18 designate an officer of the Department of Health and
- 19 Human Services to serve as a liaison between the Secretary
- 20 of Health and Human Services and the Attorney General
- 21 in carrying out this Act and the amendments made by this
- 22 *Act*.
- 23 SEC. 5. DIVERSION CONTROL FEE ACCOUNT.
- Notwithstanding any other provision of law, for pur-
- 25 poses of section 111(b) of the Departments of Commerce,

- 1 Justice, and State, the Judiciary, and Related Agencies Ap-
- 2 propriations, Act, 1993 (21 U.S.C. 886a), the operation of
- 3 the diversion control program of the Drug Enforcement Ad-
- 4 ministration shall be construed to include carrying out sec-
- 5 tion 303(i) of the Controlled Substances Act (21 U.S.C.
- 6 823(i)), as added by this Act, and subsections (a)(4), (c)(2),
- 7 and (c)(3) of section 304 of the Controlled Substances Act
- 8 (21 U.S.C. 824), as amended by this Act.

9 SEC. 6 APPLICABILITY; CONSTRUCTION.

- 10 (a) APPLICABILITY.—The amendments made by this
- 11 Act shall apply with respect to any controlled substance dis-
- 12 pensed or distributed on or after the date of enactment of
- 13 this Act.
- 14 (b) Construction.—Nothing in this Act or amend-
- 15 ments made by this Act shall be construed to imply that
- 16 the dispensing or distribution of a controlled substance be-
- 17 fore the date of enactment of this Act for the purpose of
- 18 causing, or assisting in causing, the suicide or euthanasia
- 19 of any individual is or is not a violation of the Controlled
- 20 Substances Act (21 U.S.C. 801 et seq.).
- 21 (c) Incorporated Definitions.—In this section, the
- 22 terms "controlled substance", "dispense", and "distribute"
- 23 have the meanings given those terms in section 102 of the
- 24 Controlled Substances Act (21 U.S.C. 802).

Amend the title so as to read: "To clarify Federal law to prohibit the dispensing or distribution of a con-

trolled substance for the purpose of causing, or assisting in causing, the suicide or euthanasia of any individual.".